Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaIrinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung CancerAvelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerA Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesSHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell CancerStudy of Irinotecan and Bortezomib in Children With Recurrent/Refractory NeuroblastomaIrinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerSecond Line Chemotherapy for S-1 Refractory Advanced Gastric CancerEfficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) ExpressionsSafety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular CarcinomaA Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)Phase I Study of Gimatecan in Patients With Myelodysplastic SyndromesAerosol L9-NC and Temozolomide in Ewing's SarcomaA Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid TumorsA Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsIrinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By SurgerySafety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal CancerDose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid TumorsCombination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal CancerCarboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung CancerCombination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric PatientsSafety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid TumorsMulticenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal CancerIrinotecan and Bevacizumab for Recurrent Ovarian CancerARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerSelecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal CancerCombination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic CancerMultimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk NeuroblastomaPhase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid MalignanciesAn Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed NeuroblastomaIrinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast CancerA Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersEvaluation of FDOPA-PET/MRI in Pediatric Patients With CNS TumorsA Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRCThe Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric CancerIndividualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal CancerSafety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With HepatomaSafety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
P4844
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosisTopoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.Single-antibody, targeted nanoparticle delivery of camptothecin.New plant sources of the anti-cancer alkaloid, camptothecine from the Icacinaceae taxa, India.Evidence that camptothecin-induced aberrations in the G(2) phase of cell cycle of Chinese hamster ovary (CHO) cell lines is associated with transcription[Camptothecin and derivatives: a new class of antitumor agents]
P921
Q61862239-6615D38C-A489-4832-B1B4-BAD2A8533A83Q61905049-B152AF79-EB92-4D00-BFE6-3E1D54A6EBE4Q61907081-1448E44C-7B5B-421B-8DFB-4B21CCAA34C8Q61907114-A4EEC5B9-8A8B-4CB3-AAE0-2B19F658D482Q61907461-0E2377AF-A18C-4C98-9381-6BE02C3AE389Q61914507-574D3B8F-7CBD-4996-A8C5-E6134059C396Q61914995-0C3D37BC-3375-4AD8-94D7-8A4C96B61B38Q61915034-4ABCBBD3-DEE8-468C-A0B4-E2700E66483BQ61915271-41EA3416-F13C-4221-A717-90634337C7D3Q61915422-F83D689D-AF74-4E72-ADAF-18BE58B1C050Q61917405-E3364C66-5630-4516-9BFF-EC5BF01CEDCCQ61917790-E24A2A2B-3DA2-4A51-8BE8-28BB43E11172Q61917911-B06034A6-43CF-4557-A7A6-1EF3B637BEF2Q61918369-52C391C3-6D68-4A29-B365-C8BF7A2F143FQ61920661-23856B2B-5876-406F-9257-DAD397E33A88Q61920860-BB07EAD1-B131-4109-AC3E-FA792DACA3DCQ61921674-E7CD12A8-91AF-47B0-9A1F-F1EEBAE48E5CQ61921751-DCCD3634-78E3-433A-BCFD-532EA116C53FQ61921975-2E6C1D30-B39B-43F8-A1B0-453F33C83D68Q61922873-CD44A0AC-6C87-439D-84D3-AD9635A83778Q61923094-D244472A-4232-432B-B0AC-B85084915FFBQ61924252-F9C5F27E-D68B-4E0E-A4DA-647ADF829AD3Q61934554-76A0AF3E-4272-4B74-8C51-6C392BCB2AE7Q61934934-1B5F1F1D-6356-4FFA-B493-4A176DF78082Q61937103-9678F6AC-0193-4A43-A8CC-8CCB57490847Q61938280-D5F3CE9D-8FF3-4823-B7CE-BC8BC65EE4ADQ61938666-09992DFB-ADCD-4374-AB4D-04D0A9B7FAFCQ61955362-02B68399-349E-445D-B63F-4FA227945CEFQ61956087-D68220FA-BE73-4C95-BE93-B27C7D95DDADQ61956821-7C156941-88AC-4DFF-B852-ED82C393210BQ61956987-55EFA00B-E45F-4752-9D3C-873DD537A9E5Q61957081-251CB543-B90C-4557-BEF3-955C6FA0C1CAQ61957566-092E2E8D-D17B-4DAB-AE26-C23EE5A88EA0Q61967222-43761106-BC5D-4F0C-9B98-BA770F029E2FQ61969382-9AFB8360-CA35-49CF-9BF9-AF1F25205D28Q61969616-4BE286B8-A358-493F-ABA0-1D7EE3027BE4Q61975874-F86E8275-B85C-4CA8-8A70-633EB56E0F74Q61975947-F082FBFE-39F4-47DB-8377-CB65D360E2FFQ61981371-B9BD5DB7-0430-4085-909C-7D52BBAC7915Q61981419-9E41E13D-75D0-4DBA-A3C4-F87770429352
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Camptotecina
@es
Camptotecină
@ro
Camptothecin
@de
Camptothecin
@vi
Camptothecine
@nl
Camptothécine
@fr
Kamptotecin
@sh
Kamptotecin
@sr-el
Kamptotekin
@hr
Kamptotesiini
@fi
type
label
Camptotecina
@es
Camptotecină
@ro
Camptothecin
@de
Camptothecin
@vi
Camptothecine
@nl
Camptothécine
@fr
Kamptotecin
@sh
Kamptotecin
@sr-el
Kamptotekin
@hr
Kamptotesiini
@fi
altLabel
(+)-camptothecin
@en
(+)-camptothecine
@en
(s)-(+)-camptothecin
@en
(s)-camptothecin
@en
20(S)-Camptothecin
@en
20(S)-camptothecine
@en
21,22-Secocamptothecin-21-oic acid lactone
@en
7689-03-4
@fr
C20H16N2O4
@fr
C20H16N2O4
@sr
prefLabel
Camptotecina
@es
Camptotecină
@ro
Camptothecin
@de
Camptothecin
@vi
Camptothecine
@nl
Camptothécine
@fr
Kamptotecin
@sh
Kamptotecin
@sr-el
Kamptotekin
@hr
Kamptotesiini
@fi
P4964
P486
P592
P6366
P638
P646
P661
P662
P665
P683
P1579
P2017
CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O